Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Tyler M. Maclay
Observed name:
Tyler Maclay
Institution:
Tufts University
Observed institutions:
Tufts University,
Cyteir Therapeutics (United States)
ORCID:
0000-0001-5373-7266
Observed ORCID:
0000-0001-5373-7266
OpenAlex ID:
A5016645669
Abstract P2-05-05: RAD51 inhibition using CYT-0851, shows anti-cancer activity in cellular models of breast cancer and acts synergistically with PARP inhibitors
2020
·
Joey L Guy
, Tyler Maclay
, et al.
·
Cancer Research
·
10
The DNA replication checkpoint targets the kinetochore to reposition DNA structure-induced replication damage to the nuclear periphery
2025
·
Tyler M. Maclay
, Jenna M. Whalen
, et al.
·
Cell Reports
·
9
PDF
Abstract 363: CYT01B, a novel RAD51 inhibitor, acts synergistically with PARP inhibitors
2019
·
Tyler Maclay
, Melinda Day
, et al.
·
Cancer Research
·
6
CYT01B, a Novel RAD51 Inhibitor, Act Synergistically with Both Targeted and Chemotherapeutic Anti-Cancer Agents
2018
·
Tyler Maclay
, Joseph Vacca
, et al.
·
Blood
·
6
Overcoming natural replication barriers formed by DNA structures and the role of repositioning to the nuclear periphery
2025
·
Jan Leendert Boer
, Tyler M. Maclay
, et al.
·
DNA repair
·
5
Targeting Homologous Recombination in Lymphoid Malignancies: Evaluation of Four Small Molecule Inhibitors of RAD51
2019
·
Melinda Day
, Tyler Maclay
, et al.
·
Blood
·
1
Abstract 4730: A novel RAD51 inhibitor, CYT01B, shows anti-cancer activity in preclinical models of AID expressing solid tumors
2019
·
Melinda Day
, Tyler Maclay
, et al.
·
Cancer Research
·
1
Early Role of Rif1 in the Repair of P‐element Transposase‐Induced DNA Double Strand Breaks
2021
·
Manan Krishnamurthy
, Justin Blanch
, et al.
·
The FASEB Journal
Abstract 363: CYT01B, a novel RAD51 inhibitor, acts synergistically with PARP inhibitors
2019
·
Tyler Maclay
, Melinda Day
, et al.
·
Experimental and Molecular Therapeutics
Abstract 4730: A novel RAD51 inhibitor, CYT01B, shows anti-cancer activity in preclinical models of AID expressing solid tumors
2019
·
Melinda Day
, Tyler Maclay
, et al.
·
Experimental and Molecular Therapeutics
Abstract 2566: CYT01B suppresses RAD51 focus formation and induces replication catastrophe following AID induced DNA damage
2019
·
Melinda Day
, Amber Cyr
, et al.
·
Cancer Research
Abstract 347: Targeting the AICDA/RAD51 axis: A novel gain-of-function synthetic lethal therapy for the treatment of AICDA-expressing cancers
2018
·
Muneer Hasham
, Kin-hoe Chow
, et al.
·
Cancer Research
Abstract 2481: RAD51 and AICDA define a new synthetic lethal interaction that is targetable in multiple tumor types
2017
·
Kevin D. Mills
, Marly I. Roche
, et al.
·
Cancer Research
Show more works
View as search
Works count:
13
Citation count:
38
H-index:
5
I10-index:
1
Year
Topic
Type